| Dr Alexander Pike Lemon, MD | |
|
1000 W Carson St, Torrance, CA 90502-2004 | |
| (310) 222-3501 | |
| (310) 782-1763 |
| Full Name | Dr Alexander Pike Lemon |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 1000 W Carson St, Torrance, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073718250 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A98262 (California) | Primary |
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.
The MDI Biological Laboratory has announced that Life Biosciences, a biotech company co-founded by David Sinclair, Ph.D., a leading researcher on aging and age-related diseases, has contributed $100,000 to fund its biomedical innovation course on aging.
Lotus Tissue Repair, Inc. today announced the closing of a $26 million Series A financing led by Third Rock Ventures. Proceeds of the financing will be used to advance the company's proprietary recombinant collagen type VII (rC7) technology as the first and only protein replacement therapy in development for the treatment of dystrophic epidermolysis bullosa (DEB), an orphan disease that causes devastating skin blisters, morbidity and early mortality.
Nationalistic behavior by governments may exclude some countries from gaining access to COVID-19 vaccines and cost the global economy up to $1.2 trillion a year in GDP, according to a new study from the not-for-profit research organization RAND Europe.
CSL Behring announced today that it has been granted Orphan Drug Designations by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP), a novel therapy to treat hemophilia A and hemophilia B patients with inhibitors.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alexander Pike Lemon, MD 719 S Broadway Apt 3b, Redondo Beach, CA 90277-4669 Ph: (310) 750-5052 | Dr Alexander Pike Lemon, MD 1000 W Carson St, Torrance, CA 90502-2004 Ph: (310) 222-3501 |
News Archive
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.
The MDI Biological Laboratory has announced that Life Biosciences, a biotech company co-founded by David Sinclair, Ph.D., a leading researcher on aging and age-related diseases, has contributed $100,000 to fund its biomedical innovation course on aging.
Lotus Tissue Repair, Inc. today announced the closing of a $26 million Series A financing led by Third Rock Ventures. Proceeds of the financing will be used to advance the company's proprietary recombinant collagen type VII (rC7) technology as the first and only protein replacement therapy in development for the treatment of dystrophic epidermolysis bullosa (DEB), an orphan disease that causes devastating skin blisters, morbidity and early mortality.
Nationalistic behavior by governments may exclude some countries from gaining access to COVID-19 vaccines and cost the global economy up to $1.2 trillion a year in GDP, according to a new study from the not-for-profit research organization RAND Europe.
CSL Behring announced today that it has been granted Orphan Drug Designations by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP), a novel therapy to treat hemophilia A and hemophilia B patients with inhibitors.
› Verified 8 days ago
Dr. Gina L Sulmeyer, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3330 Lomita Blvd, Torrance, CA 90505 Phone: 310-517-4785 | |
Dr. Manpreet Singh, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 W Carson St, Torrance, CA 90502 Phone: 310-222-3501 Fax: 310-782-1763 | |
Ryan Gleber, MD, BS Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3330 Lomita Blvd, Torrance, CA 90505 Phone: 310-325-9110 | |
Dr. Daena Sarah Watcha, MD, MS Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 W Carson St, Torrance, CA 90502 Phone: 310-222-3501 Fax: 310-782-1763 | |
Mary Sun, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3330 Lomita Blvd, Dept Of Emergency Medicine, Torrance, CA 90505 Phone: 310-717-6381 | |
Robert L.r. Gibbs, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 24325 Crenshaw Blvd, # 283, Torrance, CA 90505 Phone: 424-777-6642 Fax: 877-223-4535 | |
Dr. Shannon M Stacy, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3330 Lomita Blvd, Torrance Memorial Medical Center, Torrance, CA 90505 Phone: 310-325-9110 |